Department of Urology, Royal Surrey County Hospital, Guildford, United Kingdom.
Department of Urology, Royal Surrey County Hospital, Guildford, United Kingdom.
Urology. 2021 Mar;149:122-128. doi: 10.1016/j.urology.2020.12.015. Epub 2020 Dec 24.
To assess treatment satisfaction and decision regret post robot-assisted radical prostatectomy (RARP) and correlate these with clinical, demographic and quality of life indicators. Our study took place at a high-volume United Kingdom center and patients were assessed at a minimum of 18 months postsurgery.
Patients who underwent RARP between June 2011 and May 2016 were invited to participate through mailed questionnaires. A total of 207 patients formed our cohort. The questionnaires included European Organization for Research and Treatment of Cancer Quality of Life of Cancer patients 30 and PR25 modules, sexual health inventory in men and Likert decisional regret scale. A Decisional Regret Scale score of >15 was used to define an outcome of high decision regret.
The mean patient age was 63 years and the mean duration of follow up was 36 months. Of the 106 responders, 51 (48%) were fully satisfied with the decision to undergo RARP and 32 (30%) recorded high regret. The mean Decisional Regret Scale score was 11.3. High decision regret associated with the length of time from RARP to questionnaire administration, higher prostate specific quality of life symptom scores and lower sexual and erectile function scores.
Our study represents the first contemporary United Kingdom series assessing decision regret following the management of localised prostate cancer with RARP. Higher regret was seen in one third of patients and was associated with worse disease-specific quality of life, sexual and erectile function measures. To minimize regret, collaborative and detailed discussion should take place pre-operatively when counselling patients about RARP. The potential longevity and impact on quality of life of these side effects should be made clear.
评估机器人辅助前列腺根治性切除术(RARP)后的治疗满意度和决策后悔,并将其与临床、人口统计学和生活质量指标相关联。我们的研究在英国的一个高容量中心进行,患者在手术后至少 18 个月进行评估。
通过邮寄问卷邀请 2011 年 6 月至 2016 年 5 月期间接受 RARP 的患者参与。共有 207 名患者构成了我们的队列。问卷包括欧洲癌症研究与治疗组织癌症患者生活质量问卷 30 项和 PR25 模块、男性性功能健康量表和李克特决策后悔量表。决策后悔量表得分>15 用于定义高决策后悔的结果。
患者的平均年龄为 63 岁,平均随访时间为 36 个月。在 106 名应答者中,51 名(48%)对接受 RARP 的决定完全满意,32 名(30%)记录了较高的后悔。决策后悔量表的平均得分为 11.3。高决策后悔与 RARP 至问卷管理的时间长短、前列腺特异性生活质量症状评分较高和性及勃起功能评分较低有关。
我们的研究代表了英国首例评估局部前列腺癌 RARP 治疗后决策后悔的当代系列研究。三分之一的患者有较高的后悔,与较差的疾病特异性生活质量、性和勃起功能测量有关。为了最大限度地减少后悔,在为患者提供 RARP 咨询时,应在术前进行协作和详细的讨论。应该明确这些副作用的潜在长期影响和对生活质量的影响。